RCUS
Arcus Biosciences, Inc.NYSEHealthcare$22.96-3.14%ClosedMarket Cap: $2.31B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.79
P/S
9.06
EV/EBITDA
-6.72
DCF Value
$-39.27
FCF Yield
-21.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.0%
Operating Margin
-156.3%
Net Margin
-142.9%
ROE
-65.8%
ROA
-31.0%
ROIC
-42.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $33.0M | 90.9% | $-114.0M | $-98.0M | $-0.92 | — |
| FY 2025 | $247.0M | 96.0% | $-386.0M | $-353.0M | $-3.29 | — |
| Q3 2025 | $26.0M | 92.3% | $-142.0M | $-135.0M | $-1.27 | — |
| Q2 2025 | $160.0M | 100.0% | $-8.0M | $-8.0M | $0.04 | — |
| Q1 2025 | $28.0M | 100.0% | $-122.0M | $-112.0M | $-1.14 | — |
| Q4 2024 | $26.0M | 100.0% | $-103.0M | $-94.0M | $-1.03 | — |
| FY 2024 | $258.0M | 100.0% | $-330.0M | $-283.0M | $-3.14 | — |
| Q3 2024 | $48.0M | 100.0% | $-105.0M | $-92.0M | $-1.01 | — |
| Q2 2024 | $39.0M | 100.0% | $-106.0M | $-93.0M | $-1.02 | — |
| Q1 2024 | $145.0M | 100.0% | $-16.0M | $-4.0M | $-0.05 | — |
| Q4 2023 | $31.0M | 100.0% | $-91.0M | $-81.0M | $-1.08 | — |
| FY 2023 | $117.0M | 100.0% | $-340.0M | $-307.0M | $-4.15 | — |